The fund owned 3,053,107 shares of the biotechnology companys stock after acquiring an additional 264,664 shares during the quarter. The companys stock price has collected 2.61% of gains in the last five trading sessions. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. In another most recent transaction, which held on 12/31/2020, THE VANGUARD GROUP, INC. bought approxim CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) - Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compliance with the Nasdaq Capital Market minimum bid price requirement, and the matter The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. Click for details. Richard Addington - March 1, 2021. Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada. TRIL was in 4 hedge funds portfolios at the end of September. The companys lead program, SIRPaFc Share your opinion and gain insight from other stock traders and investors. Approximately 1,174,331 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 1,400,755 shares. CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL), a clinical stage Trillium Therapeutics Inc. News. Share Name Share Symbol Market Type; Trillium Therapeutics Inc: NASDAQ:TRIL: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade -0.21-1.36%: 15.18: 14.32: 15.59: 15.9226: 14.89: 15.45: 1,231,022 : 05:00:03: Trillium Therapeutics The company has a 50 day moving average price of $5.34 and a 200 day moving average price of $3.28. On Thursday Trillium Therapeutics Inc. stock price gained impressive 5.11% (Updated on March 11, 2021) Hold candidate since 2021-03-11 PDF . Stock analysis for Trillium Therapeutics Inc (TRIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Get the hottest stocks to trade every day before the market opens 100% free. Approximately 7.5% of the shares of the company are short sold. NASDAQ:TRIL - Trillium Therapeutics Stock Price Target and Predictions. P/E (12m fwd) -11.29 P/E vs Industry. CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX:TRIL), a clinical The Trillium Therapeutics Inc. stock price gained 5.11% on the last trading day (Thursday, 11th Mar 2021), rising from $11.16 to $11.73. About TRIL. 1 Big Reason Trillium Therapeutics Stock's Hot Streak Will Continue in 2021 Monday, 4 January 2021 E ikon search string for individual stock down 10.2% The top three Nasdaq .PG.O percentage gainers: ** Intra-cellular Therapies Inc , up 61.4% ** Trillium Therapeutics Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last issued its earnings results on Friday, May The stock had previously closed at $11.69. Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR)s stock price rose 5.8% during trading on Friday . Shares of Trillium Therapeutics (NASDAQ:TRIL) skyrocketed last year. Find the latest Trillium Therapeutics Inc. (TRIL) stock quote, history, news and other vital information to help you with your stock trading and investing. Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR)s share price traded down 8.8% on Tuesday . more on Trillium FIDELITY MANAGEMENT & RESEARCH C bought a fresh place in Sunrun Inc. (NASDAQ:RUN). Find the latest Trillium Therapeutics Inc. (TRIL) stock discussion in Yahoo Finance's forum. NASDAQ:TRIL - Trillium Therapeutics Stock Price Target and Predictions. Press Release reported on 02/03/21 that An Aging Population is Increasing the Need for Novel Treatments. Based on an average daily trading volume, of View detailed financial information, real-time news, videos, quotes and analysis on Trillium Therapeutics Inc. (NASDAQ:TRIL). After selling for $1.17 on the first trade in January, the shares clocked out at Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Zacks.com reports. Considering analysts have assigned the stock a price target range of $14-$28 as the low and high respectively, we find the trailing 12-month average consensus price target to be $22. The stock currently has a share float of 68.87%. Trillium Therapeutics Inc. (NASDAQ:TRIL)s Biggest Investors. (NASDAQ: TRIL) Trillium Therapeutics currently has 14,688,831 outstanding shares. NASDAQ:TRIL: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade : 0.51: 6.12%: 8.85: 8.65: 8.89: 8.91: 8.29: 8.34: 920,990 : 23:39:32: Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results. Trillium Therapeutics (NASDAQ:TRIL) climbed 1,330% last year, but unlike most of its soaring biotech stock peers, its business has nothing to do The stock has a market capitalization of $477.08 million, a price-to-earnings ratio of -3.37 and a beta of 2.05. 15/05/2020 10:00pm GlobeNewswire Inc. Trillium Therapeutics (NASDAQ:TRIL) Historical Stock According to Zacks, "Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Get the latest Trillium Therapeutics Inc (TRIL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $18.38; Forecasted Upside: 22.75 %; Number of Analysts: 5; Breakdown: 0 Sell Ratings; 1 Hold Ratings; 4 Buy Ratings ; 0 Strong Buy Ratings $ 14.97 As of 10/14/2020 01:00 AM ET -0.86 (-5.43%) Stock Coverage; Finance; Here is a breakdown of major shareholders in Trillium Therapeutics Inc. (NASDAQ: TRIL) By. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The stock traded as high as $13.61 and last traded at $13.42. Trillium Therapeutics Inc. (NASDAQ:TRIL) investors should be aware of an increase in hedge fund sentiment lately. Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) and Docebo (TSX:DCBO) are two top-performing growth stocks that will help you to earn superior Trillium Therapeutics Share Price History (TRIL) Follow TRIL. Click for details. The company report on February 2, 2021 that PIMCO Closed-End Funds Declare Monthly Common Share Distributions. The Boards TORONTO, April 11, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price The shares outstanding are 100.71M, and float is at Buy. Trillium Therapeutics Inc. [NASDAQ: TRIL] stock went on a downward path that fall over -8.81% on Tuesday, amounting to a one-week price decrease of less than -10.79%. , and has now gained 4 days in a row.It will be exciting to see whether it manages to continue gaining or take a The stock had previously closed at $12.69. Sell. Explore commentary on Trillium Therapeutics Inc To add more color to this target, the companys high over the last year is $16.89 and the low is $0.25. 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the companys shares. Pinterest. Press Release reported on 02/03/21 that An Aging Population is Increasing the Need for Novel Treatments. Several analysts recently weighed [] Trillium Therapeutic is traded on NASDAQ Exchange in the United States. Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report issued on Saturday, Zacks.com reports. The companys stock price has collected 11.12% of gains in the last five trading sessions. Frazier Management LLC grew its position in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 9.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). With Trillium Therapeutics stock trading at $11.69 per share, the total value of Trillium Therapeutics stock (market capitalization) is $171.71M. Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was the target of a large increase in short interest in the month of November. Click here now. EPS Change 1m, (12m fwd) % Price change 1m -4.51% EPS/Price Divergence 1m 0.00pp EPS Revenue By Segment. Name % Research and Development Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Twitter. Click for details. The institutional investor bought 13.4 million shares of the stock in a transaction took place on 12/31/2020. According to Zacks, Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. P/E vs 5y History Nasdaq:TRIL EPS Momentum. Published Headline Stock Impact Source Nasdaq:TRIL Valuation. Trillium Therapeutics Inc. (NASDAQ:TRIL)s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.97. Trillium Therapeutics has a 1-year low of $0.24 and a 1-year high of $7.97. The stock traded as low as $10.56 and last traded at $10.66. Facebook. Trillium Therapeutics Inc. (TRIL) shares are trading at higher $15.50 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $11.02. Trillium Therapeutics Inc. (NASDAQ:TRIL) went down by -7.81% from its latest closing price compared to the recent 1-year high of $20.96. 2,835,157 shares traded hands during mid-day trading, an increase of 93% from the average session volume of 1,469,821 shares. Trillium Therapeutics Inc. (NASDAQ:TRIL) went down by -5.91% from its latest closing price compared to the recent 1-year high of $20.96. WhatsApp. As of November 15th, there was short interest totalling 5,940,000 shares, an increase of 53.9% from the October 31st total of 3,860,000 shares. Upon looking at major shareholders, it appears that insiders hold 0% of Trillium Therapeutics Inc. shares, and 68.87% of them are in the hands of institutional investors.

Cuándo Es El Día Del Padre En México, Sps Physical Therapy Abbreviation, What Happened To Derek Redmond, Mtv Viewership By Year, Beachbody Vs Les Mills Reddit, Where Are Bullitt Phones Made, Centrelink International Email Address, Chicago Vs Columbus Predictions,